Back to Search
Start Over
Ligand initiated with bullish view at Oppenheimer, here's why
- Source :
- The Fly. October 2, 2024
- Publication Year :
- 2024
-
Abstract
- Oppenheimer analyst Leland Gershell initiated coverage of Ligand Pharmaceuticals with an Outperform rating and $135 price target. Ligand has access to potential royalty streams from over 70 assets as a [...]
Details
- Language :
- English
- Database :
- Gale General OneFile
- Journal :
- The Fly
- Publication Type :
- Periodical
- Accession number :
- edsgcl.810934454